CBD can "inhibit" Myeloma?

CBD can “inhibit” Myeloma?

According to the study linked below, yes, CBD can inhibit myeloma. For as long as I can remember, people have hoped that cannabidiol aka CBD, was cytotoxic to cancer. Studies confirming this were no were to be found as far as I knew.

Full disclosure- the study is in vitro aka in test tubes, not in myeloma patients. Also, the study cites “a time and dose dependent manner” which I take to me the more, the longer, the more effective.

Cannabinoids and Myeloma with Dr Michael Verbora

What types of cancer do cannabinoids inhibit?

Here are some types of cancer for which cannabinoids have shown inhibitory effects in preclinical models:

1. Brain Cancer (Glioblastoma)

Cannabinoids, particularly THC and CBD, have been shown to inhibit the growth of glioblastoma cells in laboratory studies. They may work by inducing apoptosis and reducing tumor cell invasiveness.

2. Breast Cancer

CBD has demonstrated the ability to inhibit the growth and spread of breast cancer cells, including triple-negative breast cancer, which is a more aggressive form.

3. Lung Cancer

Cannabinoids have been reported to reduce the growth and metastasis of lung cancer cells in animal models.

4. Prostate Cancer

Studies suggest that cannabinoids can slow the growth of prostate cancer cells and may inhibit the androgen receptor pathway, which is important for prostate cancer development.

5. Colorectal Cancer

Both THC and CBD have shown potential to reduce the growth of colorectal cancer cells in preclinical studies.

6. Pancreatic Cancer

Research indicates that cannabinoids may slow pancreatic tumor growth and increase cancer cell sensitivity to chemotherapy.

7. Melanoma (Skin Cancer)

Cannabinoids may reduce the viability of melanoma cells and suppress their ability to metastasize.

8. Leukemia and Lymphoma

Cannabinoids have demonstrated apoptosis-inducing effects on leukemia and lymphoma cells in preclinical studies.

9. Liver Cancer (Hepatocellular Carcinoma)

Studies suggest that cannabinoids may inhibit liver cancer cell growth and promote apoptosis.

Mechanisms of Action

Induction of apoptosis: Cannabinoids can trigger programmed cell death in cancer cells.
Anti-proliferative effects: They inhibit the division and growth of cancer cells.
Inhibition of angiogenesis: Cannabinoids may prevent the formation of new blood vessels that tumors need to grow.
Reduction of inflammation: Chronic inflammation is associated with cancer progression, and cannabinoids may reduce inflammation.
Prevention of metastasis: They may inhibit the ability of cancer cells to spread to other tissues.

Important Notes

Preclinical vs. Clinical Evidence: Most evidence comes from preclinical studies (cell cultures and animal models). Clinical trials in humans are limited and have yet to confirm these effects comprehensively.
Individual Variability: The efficacy of cannabinoids may depend on the type of cancer, its stage, and individual genetic factors.
Adjunctive Use: Cannabinoids are also studied for their role in managing cancer symptoms like pain, nausea, and loss of appetite, as well as side effects of chemotherapy.

I am a myeloma survivor living with a host of long-term side effects from my conventional chemo and radiation.

I squirt a couple of eye droppers of CBD oil under my tongue just before bed. I take a brand called Charlotte’s Web- no THC. I am not looking for CBD to cure multiple myeloma. However, there are good studies that document CBD as a complementary cancer therapy to reduce pain, nausea, to enhance bone mineral density and to induce sleep.

Email me at David.PeopleBeatingCancer@gmail.com with questions about CBD and myeloma.

Thank you,

David Emerson

MM Survivor
MM Cancer Coach
Director PeopleBeatingCancer

Inhibition of Myeloma Cell Function by Cannabinoid-Enriched Product Associated With Regulation of Telomere and TP53

“Multiple myeloma is a hematological cancer caused by the uncontrolled proliferation of abnormal plasma cells in the bone marrow, leading to excessive immunoglobulin production. Our study aimed to examine the anticancer properties of BRF1A, a cannabinoid (CBD)-enriched product, on 2 myeloma cell lines: U266 and ARH-7.

We treated U266 and ARH-77 myeloma cells with varying doses of BRF1A and measured the production of IgE and IgG antibodies using ELISA. Cell viability was assessed using trypan blue and CCK-8 assays.

We measured the expression of genes related to the production of IgE and IgG antibodies, IgEH, and IgGH. We determined its effect on the expression of telomerase and its phosphorylated form as an indicator of telomere stabilization.

Furthermore, we determined its effect on other cancer-related targets such as NF-ĸB, c-Myc, and TP53 in U266 cells using reverse transcription polymerase chain reaction (RT-PCR) and western blotting.

BRF1A reduced myeloma cell IgE and IgG production in a time and dose-dependent manner. It also suppressed the expression of p-IκBα, p-NFκB (p65), and total NFκB protein, as well as XBP1u and XBP1s.

It increased the gene and protein expression of telomere and hTERT and significantly increased cancer suppressor TP53 gene and p53 protein expression. Additionally, BRF1A decreased the c-Myc gene and protein expression.

Our study has shown that a CBD-enriched product can reduce the growth of myeloma cells by suppressing the critical functions of IgE- and IgG-producing cells. This study could help bridge the gap in understanding how cannabinoid-containing products affect cancer, aging, telomere, and cancer-suppressor gene activity…

CBD can inhibit myeloma CBD can inhibit myeloma

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission